These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26498537)

  • 1. Circulating microribonucleic acids miR-1, miR-21 and miR-208a in patients with symptomatic heart failure: Preliminary results.
    Sygitowicz G; Tomaniak M; Błaszczyk O; Kołtowski Ł; Filipiak KJ; Sitkiewicz D
    Arch Cardiovasc Dis; 2015 Dec; 108(12):634-42. PubMed ID: 26498537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Value of Circulating Microribonucleic Acids miR-1 and miR-21 in Evaluating the Diagnosis of Acute Heart Failure in Asymptomatic Type 2 Diabetic Patients.
    Al-Hayali MA; Sozer V; Durmus S; Erdenen F; Altunoglu E; Gelisgen R; Atukeren P; Atak PG; Uzun H
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31109008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Association of plasma amino-terminal pro-A-, B- and C-type natriuretic peptide levels with NYHA grade and echocardiographic derived parameters of cardiac function in heart failure patients].
    Zhao XY; Yang YJ; Zhang J; Kang LM; Wei BQ; Gao XJ; Lü R; Zhang CL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):486-90. PubMed ID: 19927626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Use of Circulating miR-133a and NT-proBNP Improves Heart Failure Diagnostic Accuracy in Elderly Patients.
    Guo M; Luo J; Zhao J; Shang D; Lv Q; Zang P
    Med Sci Monit; 2018 Dec; 24():8840-8848. PubMed ID: 30523241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients.
    Ellis KL; Cameron VA; Troughton RW; Frampton CM; Ellmers LJ; Richards AM
    Eur J Heart Fail; 2013 Oct; 15(10):1138-47. PubMed ID: 23696613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
    Masson S; Batkai S; Beermann J; Bär C; Pfanne A; Thum S; Magnoli M; Balconi G; Nicolosi GL; Tavazzi L; Latini R; Thum T
    Eur J Heart Fail; 2018 Jan; 20(1):78-85. PubMed ID: 29027324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
    Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
    Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study.
    Cakmak HA; Coskunpinar E; Ikitimur B; Barman HA; Karadag B; Tiryakioglu NO; Kahraman K; Vural VA
    J Cardiovasc Med (Hagerstown); 2015 Jun; 16(6):431-7. PubMed ID: 25643195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between circulating microRNAs and left ventricular mass in symptomatic heart failure patients with systolic dysfunction.
    Ikitimur B; Cakmak HA; Coskunpinar E; Barman HA; Vural VA
    Kardiol Pol; 2015; 73(9):740-6. PubMed ID: 25985726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
    McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
    J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure.
    van Boven N; Kardys I; van Vark LC; Akkerhuis KM; de Ronde MWJ; Khan MAF; Merkus D; Liu Z; Voors AA; Asselbergs FW; van den Bos EJ; Boersma E; Hillege H; Duncker DJ; Pinto YM; Postmus D
    Eur J Heart Fail; 2018 Jan; 20(1):89-96. PubMed ID: 28948688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure.
    Feola M; Aspromonte N; Canali C; Ceci V; Giovinazzo P; Milani L; Quarta G; Ricci R; Scardovi AB; Uslenghi E; Valle R
    Am J Cardiol; 2005 Sep; 96(5):705-9. PubMed ID: 16125500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study.
    Cortés R; Rivera M; Salvador A; Bertomeu V; de Burgos FG; Roselló-Lletí E; Portolés M; Payá R; Martínez-Dolz L; Climent V
    Heart; 2007 Aug; 93(8):957-62. PubMed ID: 17488774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.
    Racek J; Králová H; Trefil L; Rajdl D; Eiselt J
    Nephron Clin Pract; 2006; 103(4):c162-72. PubMed ID: 16645318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of B type natriuretic peptides with clinical and echocardiographic parameters in heterogeneous population of patients with symptoms suggestive of heart failure.
    Piechota WN; Piechota WT; Bejm J; Wierzbowski R; Michałkiewicz D
    Adv Med Sci; 2006; 51():164-7. PubMed ID: 17357300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.